Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01398852 · ClinicalTrials.gov registry record · Phase 3
Safety and Effectiveness Study of the VEGA UV-A System for Cross-linking in Eyes With Keratoconus and Ectasia
A Phase 3 study, sponsored by Topcon Medical Systems.
- Terminated
- Registry status
- Phase 3
- Development phase
- 500
- Enrollment target
NCT01398852: Clinical Trial Phase 3 study, sponsored by Topcon Medical Systems.
NCT01398852 is a Phase 3 study that was terminated before completion, run by Topcon Medical Systems. The registered enrollment target is 500 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01398852, a Phase 3 study, was terminated before completion, sponsored by Topcon Medical Systems.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 500 participants
- Enrollment target
Study Summary
The purpose of this research study is to evaluate the long tern safety and effectiveness of cross-linking in eyes with keratoconus and ectasia.
Interventions
- DRUG Riboflavin
- DEVICE VEGA UV-A Illumination System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2010-12 |
| Est. Completion | 2012-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01398852
The ClinicalTrials.gov registry entry for NCT01398852 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Topcon Medical Systems, which has 24 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Riboflavin is the first listed.
NCT01398852 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01398852 about?
NCT01398852 is a clinical study titled "Safety and Effectiveness Study of the VEGA UV-A System for Cross-linking in Eyes With Keratoconus and Ectasia". The purpose of this research study is to evaluate the long tern safety and effectiveness of cross-linking in eyes with keratoconus and ectasia.
What is the current status of trial NCT01398852?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 500 participants. The study started on 2010-12. Estimated completion is 2012-07.
What interventions are being tested in trial NCT01398852?
The interventions under investigation include: Riboflavin (DRUG), VEGA UV-A Illumination System (DEVICE).
Who is sponsoring clinical trial NCT01398852?
This trial is sponsored by Topcon Medical Systems, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.